TOLREMO therapeutics AG

Based in Switzerland, TOLREMO therapeutics AG specializes in developing innovative cancer therapies that target non-oncogene addiction through advanced mechanisms. Founded in 2017 and headquartered in Muttenz, Switzerland, TOLREMO therapeutics AG develops breakthrough cancer therapies. The company was founded by Stefanie Flückiger-Mangual, who has a history of entrepreneurship in the biotech sector. As of September 20, 2023, the company raised USD 39.

00 mn in a Series A funding round led by BioMed Partners, with participation from Pierre Fabre. The total amount raised by the company stands at USD 39. 00 mn across 4 deals. TOLREMO therapeutics specializes in developing innovative cancer therapies, focusing on addressing non-oncogene addiction through the inhibition of transcriptional escape pathways.

Their primary product is TT125-802, an orally available small molecule inhibitor targeting the bromodomain of the epigenetic regulators CBP/p300. This compound aims to disrupt transcriptional resistance mechanisms that can lead to drug resistance in cancer treatments. Positioned as a best-in-class option for treating solid tumors and hematological malignancies, TT125-802 intends to enhance patient outcomes both as a monotherapy and in combination with existing targeted therapies. The company serves healthcare providers and oncologists in Europe and North America, addressing critical cancer treatment needs.

TOLREMO therapeutics generates revenue through partnerships and collaborations with pharmaceutical companies and research institutions focused on cancer treatment. The company engages in direct B2B transactions, providing clinical compounds like TT125-802 to clinical trial partners and larger oncology-focused entities for further development and commercialization. Their business model includes licensing agreements and collaborations that facilitate the integration of TT125-802 in combination therapies, allowing for shared revenue streams derived from successful clinical applications. In September 2023, TOLREMO therapeutics AG raised USD 39.

00 mn in Series A funding to support the clinical study for phase 1 monotherapy dose escalation. The company plans to introduce new products designed to further enhance treatment options for cancer patients, with upcoming launches aimed at expanding its therapeutic portfolio. Additionally, TOLREMO aims to grow its presence in new markets, particularly targeting expansion in North America and other European regions by 2025.